Jyong Biotech Ltd. Ordinary Shares (MENS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Jyong Biotech Ltd. Ordinary Shares stock (MENS) is currently trading at $2.09. WallStSmart rates MENS as Sell.
- MENS PE ratio analysis and historical PE chart
- MENS PS ratio (Price-to-Sales) history and trend
- MENS intrinsic value — DCF, Graham Number, EPV models
- MENS stock price prediction 2025 2026 2027 2028 2029 2030
- MENS fair value vs current price
- MENS insider transactions and insider buying
- Is MENS undervalued or overvalued?
- Jyong Biotech Ltd. Ordinary Shares financial analysis — revenue, earnings, cash flow
- MENS Piotroski F-Score and Altman Z-Score
- MENS analyst price target and Smart Rating
Jyong Biotech
📊 No data available
Try selecting a different time range
Smart Analysis
Jyong Biotech Ltd. Ordinary Shares (MENS) · 2 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and institutional own.. Significant fundamental concerns warrant caution or avoidance.
Jyong Biotech Ltd. Ordinary Shares (MENS) Key Strengths (0)
Jyong Biotech Ltd. Ordinary Shares (MENS) Areas to Watch (2)
Very low institutional interest at 1.03%
Micro-cap company with very limited liquidity and high volatility
Jyong Biotech Ltd. Ordinary Shares (MENS) Detailed Analysis Report
Overall Assessment
This company scores 4/100 in our Smart Analysis, earning a F grade. Out of 2 metrics analyzed, 0 register as strengths (avg 0/10) while 2 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Institutional Own., Market Cap.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Institutional Own. improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Institutional Own. and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MENS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:05:36 AM
About Jyong Biotech Ltd. Ordinary Shares(MENS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Jyong Biotech Ltd. (ticker: MENS) is an innovative biotechnology company specializing in the development of cutting-edge therapeutic solutions for cancer and autoimmune disorders. Leveraging advanced genomics and molecular biology research, the firm boasts a promising pipeline of therapies supported by a strong intellectual property portfolio. Strategic partnerships within the biopharmaceutical sector further enhance its market position, enabling Jyong Biotech to capitalize on emerging opportunities while maintaining a steadfast commitment to scientific excellence and patient-centric care, ensuring a substantial impact on healthcare advancements.